Provident Financial Services remains a 'buy' despite recent underperformance versus the S&P 500, supported by strong year-over-year growth and a successful merger. PFS has grown deposits and loans, ...
Hosted on MSN
Coherus Biosciences Divests UDENYCA Business
An update from Coherus Biosciences ( (CHRS)) is now available. On April 11, 2025, Coherus Biosciences sold its UDENYCA business, marking a significant divestiture of its biosimilar businesses, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback